PubMed

Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.

Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber MA, Franklin S, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T; ALLHAT Collaborative Research Group.

Ann Intern Med. 2006 Feb 7;144(3):172-80.PMID: 16461961 [PubMed - indexed for MEDLINE]Related articlesFree article

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.

Arch Intern Med. 2005 Apr 25;165(8):936-46.PMID: 15851647 [PubMed - indexed for MEDLINE]Related articlesFree article

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

JAMA. 2002 Dec 18;288(23):2981-97. Erratum in: JAMA 2003 Jan 8;289(2):178. JAMA. 2004 May 12;291(18):2196. PMID: 12479763 [PubMed - indexed for MEDLINE]Related articlesFree article

Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.

Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB; ALLHAT Collaborative Research Group.

JAMA. 2005 Apr 6;293(13):1595-608.PMID: 15811979 [PubMed - indexed for MEDLINE]Related articlesFree article

Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

[No authors listed]

JAMA. 2000 Apr 19;283(15):1967-75. Erratum in: JAMA 2002 Dec 18;288(23):2976. PMID: 10789664 [PubMed - indexed for MEDLINE]Related articlesFree article

Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.

Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, Proschan MA, Thadani U, Whelton PK, Wright JT; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.

Hypertension. 2006 Sep;48(3):374-84. Epub 2006 Jul 24.PMID: 16864749 [PubMed - indexed for MEDLINE]Related articlesFree article

Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.

Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, Arnett DK.

Pharmacogenet Genomics. 2009 Jun;19(6):415-21.PMID: 19352213 [PubMed - indexed for MEDLINE]Related articles

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group.

JAMA. 2002 Nov 20;288(19):2421-31. Erratum in: JAMA. 2006 Jun 21;295(23):2726. PMID: 12435255 [PubMed - indexed for MEDLINE]Related articlesFree article

[Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial]

Scheen AJ, Krzesinski JM.

Rev Med Liege. 2003 Jan;58(1):47-52. French. PMID: 12647599 [PubMed - indexed for MEDLINE]Related articles

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group.

JAMA. 2001 Jun 6;285(21):2719-28.PMID: 11386927 [PubMed - indexed for MEDLINE]Related articlesFree article

Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C, Marginean H, Wright JT Jr, Basile J, Wong ND, Whelton P, Dart RA, Thadani U; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Diabetes Care. 2008 Feb;31(2):353-60. Epub 2007 Nov 13.PMID: 18000186 [PubMed - indexed for MEDLINE]Related articlesFree article

Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J; ALLHAT Collaborative Research Group.

Arch Intern Med. 2006 Nov 13;166(20):2191-201.PMID: 17101936 [PubMed - indexed for MEDLINE]Related articlesFree article

Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, Leenen FH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U; ALLHAT Collaborative Research Group.

Arch Intern Med. 2005 Jun 27;165(12):1401-9.PMID: 15983290 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.

Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, Arnett DK.

JAMA. 2008 Jan 23;299(3):296-307. Erratum in: JAMA. 2009 Sep 9;302(10):1057-8. PMID: 18212314 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J.

JAMA. 1996 Dec 18;276(23):1886-92. Erratum in: JAMA 1997 May 7;277(17):1356. PMID: 8968014 [PubMed - indexed for MEDLINE]Related articles

Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Wright JT Jr, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, Basile JN, Black HR, Dart R, Gupta AK, Hamilton BP, Einhorn PT, Haywood LJ, Jafri SZ, Louis GT, Whelton PK, Scott CL, Simmons DL, Stanford C, Davis BR.

Arch Intern Med. 2008 Jan 28;168(2):207-17.PMID: 18227370 [PubMed - indexed for MEDLINE]Related articlesFree article

Summaries for patients. Do the effects of blood pressure drugs differ by kidney function?

[No authors listed]

Ann Intern Med. 2006 Feb 7;144(3):I33. No abstract available. PMID: 16461958 [PubMed - indexed for MEDLINE]Related articlesFree article

Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.

Circulation. 2006 May 9;113(18):2201-10. Epub 2006 May 1.PMID: 16651474 [PubMed - indexed for MEDLINE]Related articlesFree article

Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC Jr, Ciocon JO, Sweeney ME, Randall OS; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group.

Diabetes Care. 2001 Apr;24(4):654-8.PMID: 11315826 [PubMed - indexed for MEDLINE]Related articlesFree article

Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.

Hypertension. 2003 Sep;42(3):239-46. Epub 2003 Aug 18.PMID: 12925554 [PubMed - indexed for MEDLINE]Related articlesFree article